Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · March 10, 2024

Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension

JACC: Heart Failure

 

Additional Info

Disclosure statements are available on the authors' profiles:

JACC: Heart Failure
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial
JACC Heart Fail 2023 Oct 12;[EPub Ahead of Print], A Wang, JA Spertus, DM Wojdyla, TP Abraham, EK Nilles, AT Owens, S Saberi, S Cresci, A Sehnert, NK Lakdawala

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading